Medications for Multiple Myeloma

54 results
  • Aphexda

    (Motixafortide)
    BioLineRx USA Inc
    Usage: APHEXDA is indicated, in combination with filgrastim (G-CSF), for mobilizing hematopoietic stem cells into peripheral blood for collection and autologous transplantation in patients with multiple myeloma.
  • Novadoz Pharmaceuticals LLC
    Usage: Bortezomib for injection is indicated for the treatment of adult patients with multiple myeloma and mantle cell lymphoma.
  • Accord Healthcare Inc.
    Usage: Bortezomib for injection is indicated for the treatment of adult patients with multiple myeloma and mantle cell lymphoma.
  • Hospira, Inc.
    Usage: Bortezomib for Injection is indicated for the treatment of adult patients with multiple myeloma and mantle cell lymphoma.
  • Hikma Pharmaceuticals USA Inc.
    Usage: Bortezomib for injection is indicated for the treatment of adult patients with multiple myeloma and mantle cell lymphoma.
  • NorthStar RxLLC
    Usage: Bortezomib for injection is indicated for the treatment of adult patients with multiple myeloma and mantle cell lymphoma.
  • Amneal Pharmaceuticals LLC
    Usage: BORUZU is indicated for the treatment of adult patients with multiple myeloma and mantle cell lymphoma.
  • Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.
    Usage: Carmustine for Injection, USP is indicated for palliative therapy as a single agent or in combination therapy for brain tumors (e.g., glioblastoma), multiple myeloma (with prednisone), and relapsed or refractory Hodgkin's and Non-Hodgkin's lymphomas (with other approved drugs).
  • Sandoz Inc.
    Usage: Carmustine for injection is indicated for palliative therapy as a single agent or in combination for brain tumors, multiple myeloma (with prednisone), and relapsed or refractory Hodgkin's and Non-Hodgkin's lymphomas (with other approved drugs).
  • Accord Healthcare Inc.
    Usage: Carmustine for Injection is indicated for palliative therapy in brain tumors (e.g., glioblastoma), multiple myeloma (with prednisone), and relapsed or refractory Hodgkin's and Non-Hodgkin's lymphomas (in combination with other approved drugs).